Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis
Related Experiment Video
Updated: Jun 21, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Federica Azzolini1, Luana Gilio1, Luigi Pavone1
1IRCCS Neuromed, 86077 Pozzilli, Italy.
Abstract:
Background: Astrocytes and microglia play an important role in the inflammatory process of multiple sclerosis (MS). We investigated the associations between the cerebrospinal fluid (CSF) levels of glial fibrillary acid protein (GFAP) and soluble triggering receptors expressed on myeloid cells-2 (sTREM-2), inflammatory molecules, and clinical characteristics in a group of patients with relapsing-remitting MS (RRMS). Methods: Fifty-one RRMS patients participated in the study. Clinical evaluation and CSF collection were performed at the time of diagnosis. The CSF levels of GFAP, sTREM-2, and of a large set of inflammatory and anti-inflammatory molecules were determined. MRI structural measures (cortical thickness, T2 lesion load, cerebellar volume) were examined. Results: The CSF levels of GFAP and sTREM-2 showed significant correlations with inflammatory cytokines IL-8, G-CSF, and IL-5. Both GFAP and sTREM-2 CSF levels positively correlated with age at diagnosis. GFAP was also higher in male MS patients, and was associated with an increased risk of MS progression, as evidenced by higher BREMS at the onset. Finally, a negative association was found between GFAP CSF levels and cerebellar volume in RRMS at diagnosis. Conclusions: GFAP and sTREM-2 represent suitable biomarkers of central inflammation in MS. Our results suggest that enhanced CSF expression of GFAP may characterize patients with a higher risk of progression.
Insights
Glial fibrillary acid protein (GFAP) and soluble triggering receptors expressed on myeloid cells-2 (sTREM-2) in cerebrospinal fluid (CSF) correlate with inflammation and clinical features in relapsing-remitting multiple sclerosis (RRMS). Elevated GFAP may indicate higher progression risk.
Area of Science:
- Neuroimmunology
- Biomarker Discovery
- Multiple Sclerosis Pathogenesis
Background:
- Astrocytes and microglia are key players in multiple sclerosis (MS) neuroinflammation.
- Investigating glial markers like GFAP and sTREM-2 in CSF offers insights into MS inflammatory processes.
Purpose of the Study:
- To explore the relationship between CSF GFAP and sTREM-2 levels with inflammatory molecules and clinical/MRI characteristics in relapsing-remitting MS (RRMS).
- To identify potential biomarkers for MS inflammation and progression risk.
Main Methods:
- Analysis of CSF from 51 RRMS patients at diagnosis.
- Quantification of GFAP, sTREM-2, and various inflammatory/anti-inflammatory molecules in CSF.
- Assessment of MRI structural measures including cortical thickness, T2 lesion load, and cerebellar volume.
Main Results:
- CSF GFAP and sTREM-2 levels correlated significantly with inflammatory cytokines (IL-8, G-CSF, IL-5) and positively with age at diagnosis.
- Higher GFAP levels were observed in male MS patients and associated with increased MS progression risk (higher BREMS).
- A negative association was found between CSF GFAP levels and cerebellar volume in RRMS patients at diagnosis.
Conclusions:
- GFAP and sTREM-2 are validated biomarkers for central nervous system inflammation in MS.
- Elevated CSF GFAP levels in RRMS patients may predict a higher risk of disease progression.
More Related Videos
10:40Immunofluorescence Staining Using IBA1 and TMEM119 for Microglial Density, Morphology and Peripheral Myeloid Cell Infiltration Analysis in Mouse Brain
Published on: October 27, 2019
08:17Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024